Fig. 4

DCS12-AmB-LLs were significantly more effective at reducing the number of C. albicans cells in the kidneys and A. fumigatus in the lungs than AmB-LLs in mouse models of disease. Neutropenic mice with invasive candidiasis and pulmonary aspergillosis were treated with DCS12-AmB-LLs or AmB-LLs delivering 0.2 mg/kg AmB or with liposome dilution buffer. a, b Fungal burden of C. albicans in the kidneys. c, d Fungal burden of A. fumigatus in the lungs. a, c A scatter bar plot compares the average number of CFUs per mouse kidneys or lungs for the three treatment groups. Each mouse is represented by one data point. b, d The Relative Quantity (RQ) of fungal rDNA intergenic spacer (IGS) was determined by qPCR using species specific primers on parallel samples of kidney and lung homogenates from the same mice used to assay CFUs. Three replicates qPCR reactions were run on each sample. N = 6 mice for each treatment group. Standard errors are indicated. Fold differences and T.Test determined P values or Mann–Whitney determined P_MW values are shown for informative comparisons